The Effects of Zidovudine on the Blood of HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To define the pharmacokinetic parameters (blood levels) of total phosphorylated zidovudine
(AZT) in peripheral blood mononuclear cells (PBMC) from HIV-infected patients.
Despite an understanding of the serum (or plasma) pharmacokinetics (blood levels) of AZT, a
therapeutic concentration range and optimal dosing interval have not yet been determined.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)